CN102164964A - 识别天然的膜联蛋白a3的新抗体 - Google Patents

识别天然的膜联蛋白a3的新抗体 Download PDF

Info

Publication number
CN102164964A
CN102164964A CN2009801375473A CN200980137547A CN102164964A CN 102164964 A CN102164964 A CN 102164964A CN 2009801375473 A CN2009801375473 A CN 2009801375473A CN 200980137547 A CN200980137547 A CN 200980137547A CN 102164964 A CN102164964 A CN 102164964A
Authority
CN
China
Prior art keywords
antibody
annexin
antigen
anxa3
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801375473A
Other languages
English (en)
Chinese (zh)
Inventor
S·珀兹纳诺维克
G·施瓦尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ProteoSys AG
Original Assignee
ProteoSys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ProteoSys AG filed Critical ProteoSys AG
Publication of CN102164964A publication Critical patent/CN102164964A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4718—Lipocortins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN2009801375473A 2008-09-26 2009-09-25 识别天然的膜联蛋白a3的新抗体 Pending CN102164964A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10036708P 2008-09-26 2008-09-26
US61/100,367 2008-09-26
PCT/EP2009/062470 WO2010034825A2 (en) 2008-09-26 2009-09-25 Novel antibodies recognizing native annexin a3

Publications (1)

Publication Number Publication Date
CN102164964A true CN102164964A (zh) 2011-08-24

Family

ID=41557638

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801375473A Pending CN102164964A (zh) 2008-09-26 2009-09-25 识别天然的膜联蛋白a3的新抗体

Country Status (7)

Country Link
US (1) US20110177536A1 (enExample)
EP (1) EP2344544A2 (enExample)
JP (1) JP2012503634A (enExample)
CN (1) CN102164964A (enExample)
AU (1) AU2009295842A1 (enExample)
CA (1) CA2738032A1 (enExample)
WO (1) WO2010034825A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104277102B (zh) * 2014-06-27 2017-04-12 李光辉 一种检测乳腺癌标志物Annexin A1抗原表位氨基酸序列及应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2968767B1 (fr) * 2010-12-08 2012-12-21 Biomerieux Sa Procede et coffret pour le diagnostic in vitro du cancer de la prostate
WO2013076222A1 (en) 2011-11-23 2013-05-30 Proteosys Ag Differential annexin a3 measurements of serum and blood derivatives or fractions thereof for the diagnosis of prostate cancer
FR2991777B1 (fr) * 2012-06-07 2015-08-21 Biomerieux Sa Procede de detection et/ou de dosage de l'annexine a3 d'un mammifere dans le sang ou au moins un de ses derives

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007141043A2 (en) * 2006-06-09 2007-12-13 Proteosys Ag Monoclonal anti-annexin a3 antibodies for the detection of prostate carcinoma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
AU2002220265A1 (en) * 2000-11-03 2002-05-15 University Of Vermont And State Agricultural College Compositions for inhibiting grb7

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007141043A2 (en) * 2006-06-09 2007-12-13 Proteosys Ag Monoclonal anti-annexin a3 antibodies for the detection of prostate carcinoma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOLLERMANN J ET AL: "Expression and Prognostic Relevance of Annexin A3 in Prostate Cancer", 《EUROPEAN UROLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104277102B (zh) * 2014-06-27 2017-04-12 李光辉 一种检测乳腺癌标志物Annexin A1抗原表位氨基酸序列及应用

Also Published As

Publication number Publication date
AU2009295842A1 (en) 2010-04-01
JP2012503634A (ja) 2012-02-09
WO2010034825A2 (en) 2010-04-01
US20110177536A1 (en) 2011-07-21
WO2010034825A3 (en) 2010-07-08
EP2344544A2 (en) 2011-07-20
CA2738032A1 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
JP2012524521A (ja) グリコデリンモノクローナル抗体および卵巣癌の検出におけるその使用のための方法
AU2008238258B2 (en) Autoimmune regulation of prostate cancer by annexin A3
KR20050114604A (ko) 대장암에 대한 마커로서의 니코틴아미드ｎ―메틸트랜스퍼라아제의 용도
CN102164964A (zh) 识别天然的膜联蛋白a3的新抗体
Ecke et al. Four tumour markers for urinary bladder cancer-tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation
WO2009099561A2 (en) Urinary ca125 peptides as biomarkers of ovarian cancer
JP2009540278A (ja) 前立腺癌腫の検出のためのモノクローナル抗アネキシンａ３抗体
CA2524708C (en) Use of protein cellular retinoic acid-binding protein ii (crabp ii) as marker for breast cancer
US20060257952A1 (en) Use of protein ASC as a marker for breast cancer
JP2008502891A (ja) 乳癌のマーカーとしてのタンパク質ｐｄｘ１の使用
JP4292208B2 (ja) 乳癌に対するマーカーとしてのタンパク質ｓｐｅｅの使用
HK1160869A (en) Novel antibodies recognizing native annexin a3
WO2021246153A1 (ja) 膵臓がんの検出方法及び検出試薬
Maeda et al. Blood tests for asbestos-related mesothelioma
CA2938809A1 (en) Composition and method for detecting malignant neoplastic disease
JP2004198313A (ja) 甲状腺腫瘍の診断用キット
EP1676136A1 (en) Use of protein ubc13 as a marker for breast cancer
WO2005094422A2 (en) Angiocidin fragments and uses thereof in clinical assays for cancer and other diseases
WO2005040809A1 (en) Use of protein hnrnp-f as a marker for breast cancer
Schmitt et al. BTA TRAK™-A USEFUL DIAGNOSTIC TOOL IN URINARY BLADDER CANCER?
WO2005040811A1 (en) Use of protein tip47 as a marker for breast cancer
WO2005040808A1 (en) Use of protein fkbp52 as a marker for breast cancer
WO2005040810A1 (en) Use of protein hnrnp-k as a marker for breast cancer
WO2005050217A1 (en) Use of protein pspase as a marker for breast cancer
GB2541712A (en) Autoantibody biomarkers for gastric cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1160869

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110824

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1160869

Country of ref document: HK